CERE
Closed
Cerevel Therapeutics Holdings Inc
44.96
+44.96 (0%)
Last Update: 01 Aug 2024 16:30:00
Yesterday: 0.
Day's Range: 44.96 - 44.96
Send
sign up or login to leave a comment!
When Written:
24.39
Cerevel Therapeutics Holdings Inc. is a biopharmaceutical company that is focused on developing drugs for neurological and neuropsychiatric disorders. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Cerevel's pipeline includes several drug candidates that are in various stages of development for the treatment of Parkinson's disease, epilepsy, schizophrenia, and other conditions. The company's lead drug candidate, CVL-871, is being developed for the treatment of Parkinson's disease and is currently in Phase 2 clinical trials.
Cerevel is backed by a number of high-profile investors, including Bain Capital, Pfizer, and the Bill & Melinda Gates Foundation. The company went public in October 2020 and is listed on the Nasdaq under the ticker symbol CERE.
Cerevel is led by CEO Tony Coles, who previously served as the CEO of Onyx Pharmaceuticals and Chairman and CEO of Yumanity Therapeutics. The company has a team of experienced executives and scientists who are focused on advancing its drug candidates through clinical development and ultimately bringing them to market.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Cerevel's pipeline includes several drug candidates that are in various stages of development for the treatment of Parkinson's disease, epilepsy, schizophrenia, and other conditions. The company's lead drug candidate, CVL-871, is being developed for the treatment of Parkinson's disease and is currently in Phase 2 clinical trials.
Cerevel is backed by a number of high-profile investors, including Bain Capital, Pfizer, and the Bill & Melinda Gates Foundation. The company went public in October 2020 and is listed on the Nasdaq under the ticker symbol CERE.
Cerevel is led by CEO Tony Coles, who previously served as the CEO of Onyx Pharmaceuticals and Chairman and CEO of Yumanity Therapeutics. The company has a team of experienced executives and scientists who are focused on advancing its drug candidates through clinical development and ultimately bringing them to market.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








